Irish Pharmaceutical Healthcare Association

Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health; Colm Burke (TD), Dáil Éireann, the Oireachtas; Michael Cahill (TD), Dáil Éireann, the Oireachtas; Sorca Clarke (TD), Dáil Éireann, the Oireachtas; David Cullinane (TD), Dáil Éireann, the Oireachtas; Martin Daly (TD), Dáil Éireann, the Oireachtas; Pádraig Rice (TD), Dáil Éireann, the Oireachtas; Marie Sherlock (TD), Dáil Éireann, the Oireachtas; Peter Roche (TD), Dáil Éireann, the Oireachtas; Pádraig O'Sullivan (TD), Dáil Éireann, the Oireachtas; Teresa Costello (Senator), Seanad; Manus Boyle (Senator), Seanad; Maria Byrne (Senator), Seanad; Nicole Ryan (Senator), Seanad; Tom Clonan (Senator), Seanad; Anne O'Connor (Chief Executive Officer), Health Service Executive

Intent: To take account of,and consider adopting, IPHA proposals to increase the number of clinical trials being conducted in Ireland.

Methods: EmailVirtual Meeting

Politician(s) lobbied: Anne O'Connor (Chief Executive Officer), Health Service Executive

Intent: Discuss the practical implementation of the new Framework Agreement and how to address shared challenges to achieve its objectives.

Methods: Virtual Meeting

Politician(s) lobbied: Teresa Costello (Senator), Seanad; David Cullinane (TD), Dáil Éireann, the Oireachtas; Pádraig O'Sullivan (TD), Dáil Éireann, the Oireachtas; Colm Burke (TD), Dáil Éireann, the Oireachtas

Intent: Highlighting details relating to the access to medicines environment in Ireland compared to European counterparts.

Methods: Email

Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health; Peter Burke (Minister), Department of Enterprise, Trade and Employment

Intent: Ensuring the forthcoming Life Sciences Strategy had a holistic approach from bench to bedside.

Methods: Meeting

Politician(s) lobbied: Muiris O’Connor (Assistant Secretary), Department of Health

Intent: Providing an overview from the innovative pharmaceutical industry association in the BeNeLuxa countries as a basis for further engagement in constructive dialogue on access and affordability of medicines in Europe.

Methods: Email

Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health; Peter Burke (Minister), Department of Enterprise, Trade and Employment; Colm Burke (TD), Dáil Éireann, the Oireachtas; Pádraig O'Sullivan (TD), Dáil Éireann, the Oireachtas; Ken O'Flynn (TD), Dáil Éireann, the Oireachtas; John Paul O'Shea (TD), Dáil Éireann, the Oireachtas; Niall Redmond (Assistant Secretary), Department of Health

Intent: Enhanced priority to be given to competitiveness and contribution to the European economy of the pharmaceutical sector particularly via the proposed EU BioTech Act and the Critical Medicines Act; (ii) Implementation of reforms in Draghi Report; (iii) Treatment of spending on medicines as an investment in economy and society rather than a cost.

Methods: Event / Reception

Politician(s) lobbied: Barry Andrews (MEP), European Parliament; Cynthia Ní Mhurchú (MEP), European Parliament; Michael McNamara (MEP), European Parliament; Nina Carberry (MEP), European Parliament; Regina Doherty (MEP), European Parliament; Maria Walsh (MEP), European Parliament; Seán Kelly (MEP), European Parliament; Aodhán Ó Ríordáin (MEP), European Parliament

Intent: Request a vote in the European Parliament in favour of a resolution to pause the implementation timetable of the UWWTD.

Methods: Letter

Politician(s) lobbied: Niall Redmond (Assistant Secretary), Department of Health

Intent: Finalisation of Agreement in advance of IPHA Conference.

Methods: Informal communication

Politician(s) lobbied: Muiris O’Connor (Assistant Secretary), Department of Health

Intent: Timing of requirement after enactment of new legislation should be longer to give industry better opportunity to organise.

Methods: EmailLetter

Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Muiris O’Connor (Assistant Secretary), Department of Health

Intent: Highlight IPHA's position on a National Life Sciences Strategy to cross departmental representatives.

Methods: Meeting